Results 181 to 190 of about 3,191 (210)

Aprepitant not cost effective for prevention of CINV

Inpharma Weekly, 2007
openaire   +2 more sources

Professional educational needs for chemotherapy-induced nausea and vomiting (CINV): multinational survey results from 2,388 health care providers

Supportive Care in Cancer, 2014
Amīnah Jatoi, Jatoi Amīnah
exaly  

Personalisierte CINV-Prophylaxe

Im Fokus Onkologie
openaire   +1 more source

A randomized phase III study evaluating the efficacy of single-dose NEPA, a fixed antiemetic combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC)

Annals of Oncology, 2018
Karin Jordan, M Aapro, A Dechaphunkul
exaly  

Rolapitant approved by FDA for CINV

Reactions Weekly, 2015
openaire   +1 more source

Types of CINV and risk factors

2016
openaire   +1 more source

Barriers and opportunities in CINV management

2016
openaire   +1 more source

CINV: still troubling patients after all these years

Supportive Care in Cancer, 2018
Matti Aapro, Aapro Matti
exaly  

APF530 (Granisetron Injection Extended-Release) in a Three-Drug Regimen for Delayed CINV in Highly Emetogenic Chemotherapy

Future Oncology, 2016
Lee Schwartzberg, Nashat Gabrail
exaly  

Nausea/Vomiting: Chemotherapy-Induced (CINV)

2019
openaire   +2 more sources